Gastric adenocarcinoma develops through two biologically distinct pathways. The intestinal-type pathway is driven by inflammation and progresses stepwise through the Correa cascade. It is overwhelmingly initiated by Helicobacter pylori. The diffuse-type pathway is largely de novo and is centered on loss of E-cadherin (CDH1).[1][2][3]H. pylori is a WHO Group 1 carcinogen. Only about 1–3% of infected individuals develop cancer, which reflects the combined effect of bacterial virulence (particularly CagA), host genetics, and environmental cofactors.[1][4]
The 2014 The Cancer Genome Atlas (TCGA) classification sits on top of the Lauren histologic dichotomy. It defines four subtypes:
These subtypes are independently prognostic and underpin the biomarkers that direct targeted therapy and immunotherapy: mismatch repair (MMR)/MSI, HER2, PD-L1, and EBV.[5][6][7]
About 10% of gastric cancers show familial aggregation, but only 1–3% are attributable to known germline variants. The most important of these is hereditary diffuse gastric cancer (HDGC), caused by germline CDH1 pathogenic variants. Contemporary penetrance estimates for HDGC are substantially lower than historical figures.[1][8][9]
Population-attributable risk is approximately 75% overall and approximately 89–90% for non-cardia cancer.[1][4][2]
In a prospective Japanese cohort, gastric cancer developed in infected individuals but not in uninfected individuals.[11]
A causal-inference analysis of 6.8 million Koreans estimated that H. pylori infection raised gastric cancer risk approximately 6-fold (RR 6.40, 95% CI 6.05–6.77).[12]
Cofactors that amplify risk among infected individuals include:[13]
More virulent strains
Pro-inflammatory host genotypes
High-salt or smoked diets
Low iron levels
Smoking
Hypochlorhydria from parietal cell loss permits colonization by pro-inflammatory, genotoxic non-H. pylori gastric microbiota.[13][14]
No defined precursor: Unlike intestinal-type disease, there is no well-defined precursor cascade. Tumors arise at a younger age and carry a worse prognosis.[1][27]
Mechanism:
E-cadherin is lost through somatic mutation, loss of heterozygosity, and promoter hypermethylation.
Loss destabilizes adherens junctions and disrupts cell polarity and tension sensing.
In murine models, E-cadherin loss in CD44+ gastric cells alone is sufficient to initiate multifocal signet-ring carcinoma. TP53 loss mainly accelerates progression.[28]
Molecular correlate: Diffuse-type disease maps closely onto the TCGA genomically stable subtype, which is enriched for CDH1 and RHOA mutations and CLDN18–ARHGAP fusions.[5][29]
Open question: Whether diffuse-type cancer is purely de novo, or shares early injury and field effects with the intestinal pathway, remains unresolved.[25][3]
Molecular subtype reflects tumor biology better than histology or anatomic location.[5][6][35] In a Memorial Sloan Kettering cohort of 1,438 patients, TCGA subtype was independently associated with cancer-specific survival after adjustment for stage and grade. Subtype was also more influential than tumor location in predicting treatment response.[7]
Anatomic distribution: GS and EBV+ tumors favor the proximal stomach, CIN concentrates at the gastroesophageal junction and cardia, and MSI favors the antrum.[6][36]
ACRG classification: The Asian Cancer Research Group (ACRG) scheme defines four subtypes and overlaps substantially with TCGA:[8][39][38]
MSI
MSS/EMT (mesenchymal-like)
MSS/TP53-active
MSS/TP53-inactive
The distinctive ACRG contribution is the MSS/EMT subtype. It is characterized by CDH1 loss, CLDN18–ARHGAP fusions, strong peritoneal-metastasis propensity, and the worst prognosis.
Limitations in routine practice: TCGA and ACRG subtypes are not yet routine treatment determinants.
In current practice, only MMR/MSI, HER2, PD-L1 (combined positive score), and increasingly EBV status are tested.
Both classifications derive mainly from resected primary tumors, with sparse data on premalignant and metastatic lesions.[1][8]
Second hit: Neoplastic transformation requires somatic inactivation of the second CDH1 allele.[28]
Occult intramucosal foci:
Nearly all carriers harbor microscopic intramucosal (pT1a) signet-ring cell foci.
The rate at which these foci progress to advanced cancer is poorly defined.[28][40]
Penetrance has been revised downward:
Historical estimates from high-risk kindreds were approximately 70% in men and 56% in women.[41]
NCCN-endorsed cumulative risks through age 80 are approximately 37–42% in men and 25–33% in women.[40]
In a North American cohort of families with CDH1 variants, lifetime cumulative risk of advanced gastric cancer was 10.3% in male carriers and 6.5% in female carriers.[9]
Risk is substantially higher with a strong family history; the estimate was 38% with 3 or more affected first-degree relatives.[9]
Breast cancer risk: Female carriers have an approximately 37–55% lifetime risk of lobular breast cancer, which requires separate surveillance.[9][42]
In a genotype-first European multicenter study, CDH1 pathogenic and likely pathogenic variants were positively associated with diffuse gastric cancer and lobular breast cancer.
No such association was found for missense variants of uncertain significance.[43]
Surveillance limitations and surgery:
Surveillance endoscopy has limited sensitivity for multifocal superficial signet-ring foci and usually cannot distinguish pT1a from pT1b disease.
Carriers are therefore offered risk-reducing total gastrectomy, typically between ages 20 and 30.
Surveillance is reserved for carriers who defer surgery.[27][40][44][45]
Decision-making: No genotype–phenotype predictor exists, and risk varies widely between families. Surgery-versus-surveillance decisions are therefore increasingly individualized.[9][40]
Intestinal type: Gland-forming tumors arising on a background of atrophy and intestinal metaplasia. They are associated with H. pylori and occur predominantly in older men.
Diffuse type: Poorly cohesive, often signet-ring cells infiltrating singly. Extensive mural infiltration produces a rigid, thickened stomach wall (linitis plastica).
Combined use: The Lauren classification combined with molecular subtyping, rather than exhaustive histologic typing schemes, is what currently informs trials and management.[1][39]
Diffuse-type gastric adenocarcinoma producing linitis plastica (diffuse mural thickening). Case courtesy of Dr Andrew Ryan, Radiopaedia.org, rID: 16159
Test and treat H. pylori: Testing and eradication are indicated in patients with gastric neoplasia, premalignant lesions, or a family history of gastric cancer.
Eradication reduces cancer incidence and the risk of metachronous cancer.
It incompletely reverses established metaplasia, so endoscopic surveillance remains necessary in high-risk mucosa.[1][29][17]
High-risk premalignant mucosa: The following features identify mucosa at highest risk:[2][17]
Extensive (antrum plus corpus) atrophy or intestinal metaplasia
Incomplete intestinal metaplasia
Persistent H. pylori infection
Age older than 50
Family history of gastric cancer
Biomarker testing: Testing of gastric adenocarcinoma for MMR/MSI, HER2, PD-L1, and EBV follows directly from subtype biology.[6][8][7]
MSI-high and EBV+ tumors predict checkpoint-inhibitor benefit.
Role of intestinal metaplasia: Whether metaplasia is an independent "point of no return" or a bystander is debated, as is which subset progresses. Chromosomal-instability features within metaplasia may identify progressors.[16][17][23]
Natural history in CDH1 carriers: The progression rate from pT1a foci to advanced cancer, and the optimal timing of gastrectomy versus surveillance, remain uncertain.[9][40]
Prognostic weight of EBV: The independent prognostic weight of EBV positivity is unsettled.[33][34]
Origin of diffuse-type cancer: Whether it is purely de novo or shares an early field effect with the intestinal pathway is not established.[25]
↑ 2.02.12.22.32.42.5Gawron AJ, Shah SC, Altayar O, Davitkov P, Morgan D, Turner K, Mustafa RA (2020). "AGA Technical Review on Gastric Intestinal Metaplasia—Natural History and Clinical Outcomes". Gastroenterology. 158 (3): 705–731.e5. doi:10.1053/j.gastro.2019.12.001. PMID31816300.
↑ 3.03.13.23.3Bessède E, Dubus P, Mégraud F, Varon C (2015). "Helicobacter pylori infection and stem cells at the origin of gastric cancer". Oncogene. 34 (20): 2547–55. doi:10.1038/onc.2014.187.
↑ 4.04.14.24.34.4Duan Y, Xu Y, Dou Y, Xu D (2025). "Helicobacter pylori and gastric cancer: mechanisms and new perspectives". J Hematol Oncol. 18 (1): 10. doi:10.1186/s13045-024-01654-2.
↑ 7.07.17.2Walch HS, Borpatragohain R, Jee J, et al. (2025). "Clinical implications of The Cancer Genome Atlas molecular classification system in esophagogastric cancer". Clin Cancer Res. 31 (10): 1912–1921. doi:10.1158/1078-0432.CCR-24-3473. PMID40299774Check |pmid= value (help).
↑ 10.010.110.2Baba H, Ishimoto T, Baba Y, Hayashi H, Iwatsuki M (2026). "Advances in gastric cancer research: insights into carcinogenesis, the tumor microenvironment, metastasis, and factors influencing prognosis". Ann Gastroenterol Surg. 10 (4): 984–994. doi:10.1002/ags3.70195.
↑Uemura N, Okamoto S, Yamamoto S, et al. (2001). "Helicobacter pylori infection and the development of gastric cancer". N Engl J Med. 345 (11): 784–9. doi:10.1056/NEJMoa001999. PMID11556297.
↑Oh HJ, Kim CH, Park HW, Park B (2025). "Quantifying the effects of the Correa pathway from Helicobacter pylori infection to gastric cancer: causal inference found in 6.8 million Koreans". BMC Cancer. 26 (1): 174. doi:10.1186/s12885-025-15507-9.
↑ 17.017.117.217.317.4Sugano K, Moss SF, Kuipers EJ (2023). "Gastric intestinal metaplasia: real culprit or innocent bystander as a precancerous condition for gastric cancer?". Gastroenterology. 165 (6): 1352–1366.e1. doi:10.1053/j.gastro.2023.08.028.
↑Hatakeyama M (2004). "Oncogenic mechanisms of the Helicobacter pylori CagA protein". Nat Rev Cancer. 4 (9): 688–94. doi:10.1038/nrc1433. PMID15343275.
↑Wan C, Wang P, Xu Y, et al. (2025). "Mechanism and role of H. pylori CagA-induced NLRP3 inflammasome in gastric cancer immune cell infiltration". Sci Rep. 15 (1): 14335. doi:10.1038/s41598-025-98301-8.
↑El Tekle G, Garrett WS (2023). "Bacteria in cancer initiation, promotion and progression". Nat Rev Cancer. 23 (9): 600–618. doi:10.1038/s41568-023-00594-2.
↑Müller A, He J (2023). "A double whammy on gastric cancer risk". N Engl J Med. 388 (13): 1225–1229. doi:10.1056/NEJMe2215503.
↑ 22.022.1Ajani JA, Lee J, Sano T, et al. (2017). "Gastric adenocarcinoma". Nat Rev Dis Primers. 3: 17036. doi:10.1038/nrdp.2017.36.
↑ 23.023.123.2Zhang T, Wang Z, Zhang B, Tang X (2026). "Refining the Correa cascade: gastric stem cell plasticity, niche remodelling, and parallel pathways to neoplasia". Pharmacol Res. 230: 108315. doi:10.1016/j.phrs.2026.108315.
↑Cornish SK, Choi E, Mills JC, Goldenring JR (2026). "The origins and progression of pyloric metaplasia following gastric mucosal injury". Physiol Rev. 106 (4): 2441–2471. doi:10.1152/physrev.00042.2025.
↑ 25.025.125.225.3Chen X, Wang S, Li J (2026). "Reframing early gastric carcinogenesis through lineage, niche, and evolution". Cancer Metastasis Rev. 45 (3): 67. doi:10.1007/s10555-026-10376-5.
↑Kapteijn N, Marijnissen FE, Pluimers J, et al. (2026). "Dietary factors associated with the progression of gastric intestinal metaplasia: a multicenter, prospective cohort study in a Western population". Clin Transl Gastroenterol. 17 (5): e01006. doi:10.14309/ctg.0000000000001006. Vancouver style error: initials (help)
↑ 27.027.127.2Vos EL, Salo-Mullen EE, Tang LH, et al. (2020). "Indications for total gastrectomy in CDH1 mutation carriers and outcomes of risk-reducing minimally invasive and open gastrectomies". JAMA Surg. 155 (11): 1050–1057. doi:10.1001/jamasurg.2020.3356.
↑ 29.029.129.2Liabeuf D, Oshima M, Stange DE, Sigal M (2022). "Stem cells, Helicobacter pylori, and mutational landscape: utility of preclinical models to understand carcinogenesis and to direct management of gastric cancer". Gastroenterology. 162 (4): 1067–1087. doi:10.1053/j.gastro.2021.12.252.
↑ 30.030.1Hirabayashi M, Georges D, Clifford GM, de Martel C (2023). "Estimating the global burden of Epstein-Barr virus-associated gastric cancer: a systematic review and meta-analysis". Clin Gastroenterol Hepatol. 21 (4): 922–930.e21. doi:10.1016/j.cgh.2022.07.042. PMID35963539Check |pmid= value (help).
↑ 32.032.1Yang J, Liu Z, Zeng B, Hu G, Gan R (2020). "Epstein-Barr virus-associated gastric cancer: a distinct subtype". Cancer Lett. 495: 191–199. doi:10.1016/j.canlet.2020.09.019.
↑ 33.033.133.2Zhao Y, Zhang J, Cheng A, et al. (2020). "Gastric cancer: genome damaged by bugs". Oncogene. 39 (17): 3427–3442. doi:10.1038/s41388-020-1241-4. Vancouver style error: initials (help)
↑ 34.034.1Ozawa H, Wang Y, Withers HG, et al. (2025). "MUC1-C auto-regulatory complex with EBNA1 is responsible for latent Epstein-Barr virus-associated gastric cancer progression". Oncogene. 44 (38): 3609–3624. doi:10.1038/s41388-025-03519-5.
↑ 35.035.1Felismino TC, Coimbra F (2023). "Lessons in gastric adenocarcinoma from TCGA". Nat Rev Cancer. 23 (10): 655. doi:10.1038/s41568-023-00606-1. Vancouver style error: initials (help)
↑ 36.036.1Nakamura Y, Kawazoe A, Lordick F, Janjigian YY, Shitara K (2021). "Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm". Nat Rev Clin Oncol. 18 (8): 473–487. doi:10.1038/s41571-021-00492-2.
↑Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H (2016). "Gastric cancer". Lancet. 388 (10060): 2654–2664. doi:10.1016/S0140-6736(16)30354-3.
↑ 39.039.1Chen J, Zhang X, Zhao Y (2026). "Advances in the molecular subtyping of gastric cancer". World J Surg Oncol. 24 (1): 314. doi:10.1186/s12957-026-04437-w.
↑ 40.040.140.240.340.440.5National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Esophageal, and Gastric. Version 1.2026 (updated June 16, 2026). https://www.nccn.org
↑van der Post RS, Vogelaar IP, Manders P, et al. (2015). "Accuracy of hereditary diffuse gastric cancer testing criteria and outcomes in patients with a germline mutation in CDH1". Gastroenterology. 149 (4): 897–906.e19. doi:10.1053/j.gastro.2015.06.003. PMID26072394.
↑Corso G (2022). "Pleiotropic cancer manifestations of germline CDH1 mutations: risks and management". J Surg Oncol. 125 (8): 1326–1331. doi:10.1002/jso.26847.
↑Garcia-Pelaez J, Barbosa-Matos R, Lobo S, et al. (2023). "Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes". Lancet Oncol. 24 (1): 91–106. doi:10.1016/S1470-2045(22)00643-X. PMID36436516Check |pmid= value (help).
↑Laszkowska M, Silver ER, Schrope B, et al. (2020). "Optimal timing of total gastrectomy to prevent diffuse gastric cancer in individuals with pathogenic variants in CDH1". Clin Gastroenterol Hepatol. 18 (4): 822–829.e4. doi:10.1016/j.cgh.2019.06.009.
↑Hirata Y, Noorani A, Song S, Wang L, Ajani JA (2023). "Early stage gastric adenocarcinoma: clinical and molecular landscapes". Nat Rev Clin Oncol. 20 (7): 453–469. doi:10.1038/s41571-023-00767-w.